Lupus nephritis therapy

View All

Lupus Nephritis Treatment Market Outlook and Emerging Therapies
Lupus Nephritis: A SILENT but SEVERE Systemic Lupus Erythematosus Manifestation

Lupus Nephritis (LN) is the most feared and common complication of systemic lupus erythematosus (SLE) and is responsible for the major share of morbidity and mortality of this disease. It affects around half of the systemic lupus erythematosus patients, and in ~35% of patients, lupus nephritis is the presenting fea...

Find More

Lupus Nephritis
Roche’s Gazyva receives FDA Breakthrough designation for Lupus nephritis

The US FDA has in a recent move granted Roche’s Gazyva Breakthrough Therapy Designation (BTD) for adults with lupus nephritis. Gazyva (obinutuzumab) is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug. Classified as a "monoclonal antibody", Gazyva is a CD20-directed cytolytic antibody. The drug...

Find More